Placental Extracellular Vesicle Biomarkers in Maternal Health

Abstract

Placental extracellular vesicles (EVs) have emerged as promising non-invasive biomarkers in maternal health, offering novel insights into the pathophysiology, risk stratification, and management of major obstetric complications. This review synthesizes current evidence on the biogenesis, mechanistic roles, and clinical utility of placental EV biomarkers, with a focus on their application in conditions such as preeclampsia, gestational diabetes mellitus, and fetal growth restriction. We discuss the latest research, practical implications for clinical care, and future directions for integrating placental EV profiling into precision obstetric medicine.

Introduction

Advances in molecular diagnostics have positioned placental extracellular vesicles (EVs) including exosomes and microvesicles as key players in the development of non-invasive maternal biomarkers. Produced by the syncytiotrophoblast and other placental cells, these nano-sized vesicles carry proteins, lipids, and nucleic acids that reflect both placental health and maternal-fetal interactions. The study of placental EVs has grown rapidly, driven by their accessibility in maternal blood and their potential to revolutionize risk assessment and disease monitoring in pregnancy. Here, we provide a comprehensive overview of the clinical and scientific landscape surrounding placental EV biomarkers in maternal health.

Epidemiology / Disease Burden

Hypertensive disorders of pregnancy, gestational diabetes mellitus (GDM), and fetal growth restriction (FGR) collectively affect millions of pregnancies annually and are leading contributors to maternal and perinatal morbidity and mortality worldwide. Early detection and targeted management of these conditions remain challenging due to the lack of reliable, non-invasive biomarkers that accurately reflect placental dysfunction. As a result, adverse outcomes such as preterm birth, stillbirth, and long-term metabolic disease persist despite advances in obstetric care. The identification and validation of placental EV biomarkers offer a promising pathway to address this global disease burden by enabling earlier diagnosis and personalized intervention strategies.

Pathophysiology

Placental EVs are shed into maternal circulation throughout gestation, with their concentration and cargo dynamically regulated by physiological and pathological changes. In normal pregnancy, EVs mediate maternal-fetal communication, immune tolerance, and vascular adaptation. In contrast, conditions such as preeclampsia and GDM are characterized by altered EV release profiles, including increased concentrations and changes in protein, microRNA (miRNA), and lipid content. These alterations reflect underlying placental hypoxia, inflammation, and impaired angiogenesis, providing mechanistic links between placental dysfunction and adverse outcomes. For example, EV-associated miR-210 and soluble fms-like tyrosine kinase-1 (sFlt-1) have been implicated in the pathogenesis of preeclampsia, while changes in EV-derived miR-16 and miR-21 are associated with GDM and FGR.

Risk Factors

Risk factors for abnormal placental EV profiles mirror those for major obstetric complications and include advanced maternal age, obesity, chronic hypertension, diabetes, multiple gestations, and a history of placental disorders. Specific genetic and environmental factors may also influence the biogenesis and release of placental EVs, further modulating disease risk. Importantly, exposure to smoking, infections, and environmental toxins can alter EV content and function, underscoring the complex interplay between maternal health, placental biology, and the extracellular vesicle landscape.

Clinical Features

The clinical manifestations of placental dysfunction including hypertension, proteinuria, abnormal fetal growth, and maternal metabolic derangements are often preceded by molecular changes detectable in placental EVs. Elevated circulating EV concentrations, particularly those expressing placental alkaline phosphatase (PLAP) or syncytin-1, have been reported in women who subsequently develop preeclampsia or FGR. Similarly, specific EV cargo, such as angiogenic proteins and regulatory miRNAs, can differentiate between normal and pathological pregnancies before overt clinical symptoms arise. These findings support the utility of placental EVs as early indicators of pregnancy complications, enabling proactive clinical monitoring and intervention.

Diagnosis

Current diagnostic approaches for placental dysfunction rely on clinical criteria and conventional biomarkers, which often lack sensitivity and specificity. Placental EVs offer a minimally invasive, real-time window into placental health. Techniques such as nanoparticle tracking analysis, flow cytometry, and mass spectrometry are utilized to quantify and characterize EVs in maternal plasma. Biomarker panels incorporating placental-specific proteins (e.g., PLAP, sFlt-1), miRNAs (e.g., miR-210, miR-518b), and lipid signatures are under investigation for early and accurate detection of preeclampsia, GDM, and FGR. Integration of EV profiling with clinical and imaging data holds promise for enhancing diagnostic precision and risk stratification in obstetric care.

Treatment & Management

While placental EVs are not yet used directly in clinical management, their ability to reflect disease progression and response to therapy positions them as valuable adjuncts to current protocols. Serial measurement of EV biomarkers may inform the timing of interventions such as antihypertensive therapy, corticosteroid administration, or delivery planning in high-risk pregnancies. Furthermore, understanding the molecular cargo of placental EVs provides new targets for therapeutic development, including strategies to modulate EV release or block pathogenic signaling pathways in the maternal circulation.

Recent Advances / Emerging Therapies

Recent years have witnessed significant advances in EV isolation technologies, biomarker discovery, and functional studies. High-throughput omics platforms have identified novel placental EV-associated proteins and miRNAs with diagnostic and prognostic potential. Clinical trials are underway to validate EV biomarker panels for early screening of preeclampsia and GDM. Emerging therapies aim to harness the immunomodulatory and angiogenic properties of engineered EVs for therapeutic delivery or as disease-modifying agents. These innovations are paving the way for personalized, precision-based obstetric care rooted in real-time placental monitoring.

Guideline Recommendations

While international guidelines have yet to formally incorporate placental EV biomarkers into routine clinical practice, expert consensus highlights their potential utility in high-risk pregnancy screening and monitoring. The International Society for Extracellular Vesicles and various obstetric organizations advocate for standardization of EV isolation, characterization, and reporting protocols. Recommendations emphasize the need for large-scale validation studies, integration with existing risk models, and consideration of ethical and logistical challenges prior to widespread clinical adoption.

Conclusion

Placental extracellular vesicle biomarkers represent a transformative frontier in maternal health, offering unprecedented opportunities for early detection, risk stratification, and tailored management of pregnancy complications. As technological and scientific advances continue to elucidate the mechanistic and clinical relevance of placental EVs, their integration into precision obstetric care is poised to enhance outcomes for mothers and infants worldwide. Continued interdisciplinary research and guideline development will be essential to realize the full potential of placental EV biomarkers in clinical practice.